[go: up one dir, main page]

AU2001293554A1 - Dextran-hemoglobin conjugates as blood substitutes - Google Patents

Dextran-hemoglobin conjugates as blood substitutes

Info

Publication number
AU2001293554A1
AU2001293554A1 AU2001293554A AU9355401A AU2001293554A1 AU 2001293554 A1 AU2001293554 A1 AU 2001293554A1 AU 2001293554 A AU2001293554 A AU 2001293554A AU 9355401 A AU9355401 A AU 9355401A AU 2001293554 A1 AU2001293554 A1 AU 2001293554A1
Authority
AU
Australia
Prior art keywords
dextran
blood substitutes
hemoglobin conjugates
hemoglobin
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001293554A
Inventor
Jeffrey Tze-Fei Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dextro Sang Corp
Original Assignee
Dextro Sang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dextro Sang Corp filed Critical Dextro Sang Corp
Publication of AU2001293554A1 publication Critical patent/AU2001293554A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

An hemoglobin (Hb)-Dextran (Dx) conjugate having a molecular weight between 50 kd and 500 kD provides a blood substitute that results in acceptable erythrocyte sedimentation rate (ESR) and excretion rate (EXC) values. DxHb conjugates of the invention can be used for a variety of purposes as an alternative to blood.
AU2001293554A 2000-09-19 2001-09-19 Dextran-hemoglobin conjugates as blood substitutes Abandoned AU2001293554A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2319966 2000-09-19
CA002319966A CA2319966A1 (en) 2000-09-19 2000-09-19 Improved dextran-hemoglobin conjugate as potential blood substitute
PCT/CA2001/001329 WO2002024751A1 (en) 2000-09-19 2001-09-19 Dextran-hemoglobin conjugates as blood substitutes

Publications (1)

Publication Number Publication Date
AU2001293554A1 true AU2001293554A1 (en) 2002-04-02

Family

ID=4167162

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001293554A Abandoned AU2001293554A1 (en) 2000-09-19 2001-09-19 Dextran-hemoglobin conjugates as blood substitutes

Country Status (10)

Country Link
US (2) US20030073820A1 (en)
EP (1) EP1339749B1 (en)
JP (1) JP2004509168A (en)
CN (2) CN1668643A (en)
AT (1) ATE399795T1 (en)
AU (1) AU2001293554A1 (en)
CA (1) CA2319966A1 (en)
DE (1) DE60134661D1 (en)
WO (1) WO2002024751A1 (en)
ZA (1) ZA200305580B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2795084A1 (en) * 2010-04-02 2011-10-06 Alberta Innovates - Technology Futures Polyamine-containing polymers and methods of synthesis and use
US9737232B2 (en) 2013-03-14 2017-08-22 Gyrus Acmi, Inc. Surgical positioning circuit
EP3092213B1 (en) 2013-12-27 2019-10-23 Virginia Commonwealth University Allosteric hemoglobin modifiers with nitric oxide releasing moiety
US10859563B2 (en) 2015-12-01 2020-12-08 General Electric Company Erythrocyte aggregation and leukocyte isolation
CN106620663B (en) * 2017-02-05 2020-05-19 中国医学科学院生物医学工程研究所 Preparation method and application of sugar-hemoglobin nanoparticles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1055932A (en) * 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
GB8328917D0 (en) * 1983-10-28 1983-11-30 Fisons Plc Blood substitute
FR2600894B1 (en) * 1986-07-02 1989-01-13 Centre Nat Rech Scient MACROMOLECULAR CONJUGATES OF HEMOGLOBIN, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS
GB8710598D0 (en) * 1987-05-05 1987-06-10 Star Medical Diagnostics Ltd Hemoglobin based blood substitute
FR2630329B1 (en) * 1988-04-20 1991-07-05 Merieux Inst MACROMOLECULAR CONJUGATES OF HEMOGLOBIN, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS
CA2233725A1 (en) * 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes

Also Published As

Publication number Publication date
CN1668643A (en) 2005-09-14
EP1339749A1 (en) 2003-09-03
ATE399795T1 (en) 2008-07-15
CN101569749B (en) 2011-07-13
ZA200305580B (en) 2004-07-19
JP2004509168A (en) 2004-03-25
WO2002024751A1 (en) 2002-03-28
US20050113289A1 (en) 2005-05-26
EP1339749B1 (en) 2008-07-02
CA2319966A1 (en) 2002-03-19
CN101569749A (en) 2009-11-04
US20030073820A1 (en) 2003-04-17
US7307150B2 (en) 2007-12-11
DE60134661D1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
FR13C0021I1 (en)
BR0212035A (en) Modified ix factor
DE60006100D1 (en) LONG-LASTING INSULINOTROPE PEPTIDES
BR122018071808B8 (en) conjugate
MY119768A (en) Fibre blend for enteral composition.
EP2270030A3 (en) Heterologous expression of Neisserial proteins
IL153593A (en) Pharmaceutical composition containing a soluble ctla4 mutant molecule
BG101781A (en) SOLID PREPARATION CONTAINING ACTIVE SUBSTANCE
ES2343105T8 (en) Urate oxidase without aggregates for the preparation of non-immunogenic polymeric conjugates
WO2002060955A3 (en) Modified antibodies and methods of use
EA200100610A1 (en) COOPERATIVE COOPERATION
AU9036598A (en) Methods and compositions to prevent formation of adhesions in biological tissues
FI964600A0 (en) Copolymer-1 improvements in copolymer compositions
IL112920A (en) Composition comprising a dendritic polymer complexed with at least one unit of biological response modifier and a process for the preparation thereof
EP2626368A3 (en) Insulin-oligomer conjugates, formulations and uses thereof
TR200002299T2 (en) Epothilon compositions.
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
EP1283029A3 (en) Open-Type disposable diaper
EP1790728A3 (en) Imaging, diagnosis and treatment of disease
ATE198834T1 (en) CONJUGATES CONSISTING OF POLYSACCHARIDE AND PROTEIN
IL145557A0 (en) Immunoabsorber for use in sepsis therapy
AU2001293554A1 (en) Dextran-hemoglobin conjugates as blood substitutes
FR2870242B1 (en) PEPTIDES OR PEPTIDE CONJUGATES DERIVED FROM MSH AND THEIR USE IN THE COSMETIC TREATMENT OF CANITIA.
DE69921486D1 (en) DEXTRAN-LEPTIN CONJUGATES, PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS
BG102810A (en) Method and device for the preparation of non-cellular substituent of the red blood cells